Cargando…

Functional Polymorphism in the ADRB3 Gene, Encoding the Beta-3 Adrenergic Receptor, and Response to Intra-Detrusor Injection of Botulinum Toxin-A in Women with Overactive Bladder

Background: There are reports suggesting an association between the rs4994 polymorphism in the ADRB3 gene encoding the beta-3 adrenergic receptor and OAB risk in females. The injection of botulinum toxin-A into the bladder wall is recommended as a possible treatment for OAB patients in whom first-li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciećwież, Sylwester Michał, Lewandowska, Klaudyna, Boroń, Agnieszka, Brodowski, Jacek, Kociszewski, Jacek, Clark, Jeremy Simon, Ciechanowicz, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781921/ https://www.ncbi.nlm.nih.gov/pubmed/36556105 http://dx.doi.org/10.3390/jcm11247491

Ejemplares similares

Botulinum Toxin in Neurogenic Detrusor Overactivity
por: D'Ancona, Carlos Arturo Levi, et al.
Publicado: (2012)

Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity
por: Cho, Young Sam, et al.
Publicado: (2016)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
por: Wu, Shang-Jun, et al.
Publicado: (2019)

CONCOMITANT DETRUSOR AND EXTERNAL URETHRAL SPHINCTER BOTULINUM TOXIN-A INJECTIONS IN MALE SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA
por: HUANG, Yu-Hui, et al.
Publicado: (2022)

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
por: Traini, Chiara, et al.
Publicado: (2019)

Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience
por: Mohanty, N. K., et al.
Publicado: (2008)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2022)

Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury
por: Lombardi, Giuseppe, et al.
Publicado: (2017)

Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
por: Chen, Sheng-Fu, et al.
Publicado: (2020)

Adiponectin Gene Polymorphism (rs17300539) Has No Influence on the Occurrence of Metabolic Syndrome in Women with Polycystic Ovary Syndrome
por: Nowak, Izabela, et al.
Publicado: (2021)

ADRB3, ROCK2, and GEF Levels in Overactive Bladder Patients
por: Fırat, Elif, et al.
Publicado: (2022)

Investigating Urine Biomarkers in Detrusor Underactivity and Detrusor Overactivity with Detrusor Underactivity Patients
por: Jiang, Yuan-Hong, et al.
Publicado: (2023)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016)

Association of the rs3039851 Insertion/Deletion in the Gene PPP3R1, Which Encodes the Regulatory Calcineurin Subunit B Type 1, with Left Ventricular Mass in Polish Full-Term Newborns
por: Gorący, Iwona, et al.
Publicado: (2023)

Abobotulinum - a toxin injection in patients with refractory idiopathic detrusor overactivity: injections in detrusor, trigone and bladder neck or prostatic urethra, versus detrusor - only injections
por: Emami, Maryam, et al.
Publicado: (2017)

The use of botulinum toxin for the treatment of overactive bladder syndrome
por: Orasanu, Bogdan, et al.
Publicado: (2013)

Gabapentin add-on therapy for patients with spinal cord injury associated neurogenic overactive detrusors that are unresponsive to combined anticholinergic and beta-3 adrenergic therapy
por: Cakici, Ozer Ural, et al.
Publicado: (2021)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

AB204. Repeated intradetrusor botulinum toxin type A injections are still effective for patients with neurogenic detrusor overactivity secondary to spinal cord injury in China
por: Chen, Hui, et al.
Publicado: (2016)

Estrogen and Progesterone Receptor Immunoexpression in Fallopian Tubes among Postmenopausal Women Based on Time since the Last Menstrual Period
por: Brodowska, Agnieszka, et al.
Publicado: (2021)

Alterations of the Myovesical Plexus of the Human Overactive Detrusor
por: Kuijpers, Kamiel A. J., et al.
Publicado: (2014)

Emerging treatments for overactive bladder: clinical potential of botulinum toxins
por: Tincello, Douglas G, et al.
Publicado: (2014)

Botulinum toxin-A for the treatment of overactive bladder: UK contributions
por: Seth, JH, et al.
Publicado: (2013)

Human-Specific SNP in Obesity Genes, Adrenergic Receptor Beta2 (ADRB2), Beta3 (ADRB3), and PPAR γ2 (PPARG), during Primate Evolution
por: Takenaka, Akiko, et al.
Publicado: (2012)

Role of detrusor PDGFRα(+) cells in mouse model of cyclophosphamide-induced detrusor overactivity
por: Lee, Haeyeong, et al.
Publicado: (2022)

Coexisting overactive–underactive bladder and detrusor overactivity–underactivity in pelvic organ prolapse
por: Frigerio, Matteo, et al.
Publicado: (2022)

Botulinum Toxin A Injection for Autonomic Dysreflexia—Detrusor Injection or Urethral Sphincter Injection?
por: Chow, Po-Ming, et al.
Publicado: (2023)

Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children
por: Zeino, Mazen, et al.
Publicado: (2012)

Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Hui, C, et al.
Publicado: (2016)

Autonomous Nervous System Activity in Women with Detrusor Overactivity
por: Im, Hyun Wook, et al.
Publicado: (2010)

Urinary nerve growth factor in patients with detrusor overactivity
por: Korzeniecka-Kozerska, A., et al.
Publicado: (2014)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

Investigating changes in β-adrenergic gene expression (ADRB1 and ADRB2) in Takotsubo (stress) cardiomyopathy syndrome; a pilot study
por: Tutgun Onrat, Serap, et al.
Publicado: (2021)

Two Functional TP53 Genetic Variants and Predisposition to Keloid Scarring in Caucasians
por: Dmytrzak, Andrzej, et al.
Publicado: (2019)

Increased detrusor collagen is associated with detrusor overactivity and decreased bladder compliance in men with benign prostatic obstruction
por: Bellucci, Carlos H.S., et al.
Publicado: (2017)

Correction to: Investigating changes in β‑adrenergic gene expression (ADRB1 and ADRB2) in Takotsubo (stress) cardiomyopathy syndrome; a pilot study
por: Onrat, Serap Tutgun, et al.
Publicado: (2022)

Urinary ATP May Be a Dynamic Biomarker of Detrusor Overactivity in Women with Overactive Bladder Syndrome
por: Silva-Ramos, Miguel, et al.
Publicado: (2013)

Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements
por: Javan Balegh Marand, Aida, et al.
Publicado: (2023)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gi8c9pacnr2v4tqfr9vqcm92et